Alnylam Pharmaceuticals Inc
ALNY452.222USD
+10.522+2.38%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
59.60BMarktkapitalisierung
1368.04KGV TTM
mehr Informationen über Alnylam Pharmaceuticals Inc Unternehmen
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Alnylam Pharmaceuticals Inc Informationen
BörsenkürzelALNY
Name des UnternehmensAlnylam Pharmaceuticals Inc
IPO-datumMay 28, 2004
CEODr. Yvonne L. Greenstreet, M.D.
Anzahl der mitarbeiter2230
WertpapierartOrdinary Share
GeschäftsjahresendeMay 28
Addresse675 W Kendall St
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02142-1168
Telefon16175518200
Websitehttps://www.alnylam.com/
BörsenkürzelALNY
IPO-datumMay 28, 2004
CEODr. Yvonne L. Greenstreet, M.D.
Führungskräfte von Alnylam Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
65.82K
+16.23%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
54.11K
+7.83%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
27.44K
+5.56%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.80K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+569.85%
Ms. Carolyn R. Bertozzi, M.D.
Ms. Carolyn R. Bertozzi, M.D.
Independent Director
Independent Director
775.00
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
--
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
775.00
--
Ms. Colleen F. Reitan
Ms. Colleen F. Reitan
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
65.82K
+16.23%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
54.11K
+7.83%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
27.44K
+5.56%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.80K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+569.85%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
AMVUTTRA
491.95M
63.59%
GIVLAARI
80.85M
10.45%
ONPATTRO
52.54M
6.79%
Other
50.67M
6.55%
OXLUMO
46.87M
6.06%
Andere
50.81M
6.57%
Nach RegionUSD
Name
Umsatz
Anteil
United States
454.57M
58.75%
Europe
157.01M
20.29%
Net revenues from collaborations
61.50M
7.95%
Rest of World
60.63M
7.84%
Royalty revenue
39.98M
5.17%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
AMVUTTRA
491.95M
63.59%
GIVLAARI
80.85M
10.45%
ONPATTRO
52.54M
6.79%
Other
50.67M
6.55%
OXLUMO
46.87M
6.06%
Andere
50.81M
6.57%
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Capital World Investors
12.72%
Fidelity Management & Research Company LLC
11.39%
The Vanguard Group, Inc.
10.22%
Capital Research Global Investors
5.44%
BlackRock Institutional Trust Company, N.A.
4.94%
Andere
55.28%
Aktionäre
Aktionäre
Anteil
Capital World Investors
12.72%
Fidelity Management & Research Company LLC
11.39%
The Vanguard Group, Inc.
10.22%
Capital Research Global Investors
5.44%
BlackRock Institutional Trust Company, N.A.
4.94%
Andere
55.28%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
68.97%
Investment Advisor/Hedge Fund
21.97%
Hedge Fund
3.70%
Research Firm
1.84%
Sovereign Wealth Fund
1.63%
Bank and Trust
1.27%
Pension Fund
1.27%
Corporation
1.05%
Individual Investor
0.42%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
1364
130.85M
99.04%
-1.89M
2025Q2
1300
131.78M
100.54%
-3.28M
2025Q1
1315
132.55M
101.67%
-2.42M
2024Q4
1263
130.73M
100.99%
-1.47M
2024Q3
1225
126.90M
98.51%
-1.26M
2024Q2
1183
123.30M
96.32%
+1.12M
2024Q1
1172
117.88M
93.23%
-5.46M
2023Q4
1169
120.70M
96.18%
-5.54M
2023Q3
1125
121.55M
96.89%
-6.15M
2023Q2
1119
122.11M
98.30%
-6.32M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Capital World Investors
16.81M
12.82%
+55.38K
+0.33%
Jun 30, 2025
Fidelity Management & Research Company LLC
15.05M
11.48%
+427.38K
+2.92%
Jun 30, 2025
The Vanguard Group, Inc.
13.24M
10.1%
+238.24K
+1.83%
Jun 30, 2025
Capital Research Global Investors
7.19M
5.49%
+36.93K
+0.52%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.53M
4.98%
-199.00K
-2.96%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
4.28M
3.27%
-136.87K
-3.10%
Jun 30, 2025
JP Morgan Asset Management
1.79M
1.37%
-87.08K
-4.64%
Jun 30, 2025
Dodge & Cox
3.20M
2.44%
-154.67K
-4.61%
Jun 30, 2025
State Street Investment Management (US)
3.17M
2.42%
-193.48K
-5.75%
Jun 30, 2025
T. Rowe Price Associates, Inc.
3.05M
2.32%
-359.26K
-10.55%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
Global X Genomics & Biotechnology ETF
6.7%
ProShares Ultra Nasdaq Biotechnology
6.12%
Invesco Nasdaq Biotechnology ETF
5.99%
iShares Biotechnology ETF
5.42%
Franklin Genomic Advancements ETF
5.21%
VanEck Biotech ETF
4.84%
First Trust NYSE Arca Biotechnology Index Fund
4.5%
American Century Focused Dynamic Growth ETF
4.11%
Pinnacle Focused Opportunities ETF
3.71%
Invesco NASDAQ Next Gen 100 ETF
3.42%
Mehr Anzeigen
Global X Genomics & Biotechnology ETF
Anteil6.7%
ProShares Ultra Nasdaq Biotechnology
Anteil6.12%
Invesco Nasdaq Biotechnology ETF
Anteil5.99%
iShares Biotechnology ETF
Anteil5.42%
Franklin Genomic Advancements ETF
Anteil5.21%
VanEck Biotech ETF
Anteil4.84%
First Trust NYSE Arca Biotechnology Index Fund
Anteil4.5%
American Century Focused Dynamic Growth ETF
Anteil4.11%
Pinnacle Focused Opportunities ETF
Anteil3.71%
Invesco NASDAQ Next Gen 100 ETF
Anteil3.42%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
